Psychedelic drugs trigger a sustained intracellular signaling response through serotonin 2A receptors that may help explain their long-lasting effects

Psychedelic compounds acting at serotonin 2A receptors can produce signaling that persists after the drugs are no longer present, offering a plausible molecular basis for unusually long psychological and therapeutic effects. The central focus is receptor pharmacology rather than subjective experience, linking classic psychedelics to prolonged intracellular responses. The work centers on how compounds such as LSD, psilocybin-related agonists, and DMT-family psychedelics engage 5-HT2A signaling pathways in ways that differ from shorter-acting serotonergic ligands. A key implication is that receptor location, trafficking, and downstream signaling duration may matter as much as simple receptor binding when explaining why psychedelic effects can outlast immediate drug exposure. This mechanism matters for both neuroscience and drug development. Sustained 5-HT2A signaling could help explain lasting changes in perception, cognition, and clinical outcomes, and it points toward new strategies for designing psychedelic-inspired therapeutics with more targeted or durable benefits.